spironolactone

Trade name: aldactone

Small moleculeapproved

Approved

Jan 21, 1960

Spironolactone is a synthetic 17-lactone steroid which is a renal competitive aldosterone antagonist in a class of pharmaceuticals called potassium-sparing diuretics. On its own, spironolactone is only a weak diuretic, but it can be combined with other diuretics. Due to its anti-androgen effect, it can also be used to treat hirsutism, and is a common component in hormone therapy for male-to-female transgendered people. Spironolactone inhibits the effect of aldosterone by competing for intracellular aldosterone receptor in the distal tubule cells. This increases the secretion of water and sodium, while decreasing the excretion of potassium. Spironolactone has a fairly slow onset of action, taking several days to develop and similarly the effect diminishes slowly. Spironolactone is a specific pharmacologic antagonist of aldosterone, acting primarily through competitive binding of receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. Spironolactone causes increased amounts of sodium and water to be excreted, while potassium is retained. Spironolactone acts both as a diuretic and as an antihypertensive drug by this mechanism. It may be given alone or with other diuretic agents which act more proximally in the renal tubule. Aldosterone interacts with a cytoplasmic mineralocorticoid receptor to enhance the expression of the Na+, K+-ATPase and the Na+ channel involved in a Na+ K+ transport in the distal tubule . Spironolactone bind to this mineralcorticoid receptor, blocking the actions of aldosterone on gene expression. Aldosterone is a hormone; its primary function is to retain sodium and excrete potassium in the kidneys. Spironolactone is used primarily to treat low-renin hypertension, hypokalemia, and Conn's syndrome. — NCATS

Clinical trial activity

226 trials · 248 clinical orgs · 31 marketing orgs

Phase 1
26
Phase 2
79
Phase 3
43
Phase 4
78

Earliest trial started Jan 1, 1985 (NCT00001202)

Timeline

1960s

  1. Jan 21, 1960

    G D Searle — Earliest FDA Approval

  2. Jan 21, 1960

    G D Searle — NDA Secondary Org

  3. Jan 21, 1960

    G D Searle — NDA Organization

  4. Jan 21, 1960

    Pfizer — NDA Secondary Org

1970s

  1. Aug 3, 1979

    Mylan — Marketing Organization

1980s

  1. May 7, 1980

    Ivax — Marketing Organization

  2. Jul 10, 1980

    CASI Pharmaceuticals, Inc. — Marketing Organization

  3. Jul 10, 1980

    Chartwell Pharmaceuticals — Marketing Organization

  4. Jul 10, 1980

    Fosun — Marketing Organization

  5. Jan 28, 1981

    Mutual Pharmaceutical — Marketing Organization

  6. Feb 3, 1981

    PHARMOBEDIENT — Marketing Organization

  7. Feb 23, 1981

    Watson Pharmaceuticals — Marketing Organization

  8. Dec 14, 1981

    Vanguard — Marketing Organization

  9. Aug 4, 1982

    Lederle — Marketing Organization

  10. Aug 4, 1982

    American Cyanamid — Marketing Organization

  11. Aug 15, 1983

    Ascot Pharmaceuticals — Marketing Organization

  12. Jan 1, 1985

    Earliest Phase 2 Sponsor(trial)

  13. Aug 26, 1985

    Superpharm — Marketing Organization

  14. Nov 6, 1985

    Puracap Pharmaceutical — Marketing Organization

  15. Jul 23, 1986

    Sun Pharmaceuticals — Marketing Organization

1990s

  1. Jul 29, 1999

    Actavis — Marketing Organization

2000s

  1. Jan 1, 2005

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2005

    Earliest Phase 3 Sponsor(trial)

  3. Aug 29, 2006

    Oxford Pharmaceuticals — Marketing Organization

2010s

  1. Jul 2, 2010

    Amneal Pharmaceuticals — Marketing Organization

  2. Mar 6, 2014

    Aurobindo Pharma — Marketing Organization

  3. Apr 23, 2014

    Jubilant Innovation Ltd. — Marketing Organization

  4. Sep 19, 2016

    Accord Research — Marketing Organization

  5. Aug 4, 2017

    CMP Therapeutics Ltd — NDA Secondary Org

  6. Jul 18, 2018

    Zydus Discovery DMCC — Marketing Organization

2020s

  1. Jan 23, 2025

    Graviti Pharmaceuticals — Marketing Organization

  2. Feb 21, 2025

    Hetero Labs Ltd — Marketing Organization

  3. Jul 25, 2025

    Annora Pharma — Marketing Organization

Indications

Studied for

Mechanism of action

Combination products

  • aldactazide

    with hydrochlorothiazide

    Also known as spironolactone/hydrochlorothiazide (25 mg/25 mg) film coated tablets from neolpharma.

Approval history

  • approvedPriority reviewJan 21, 1960

Chemistry & pharmacology

Loading structure…

SMILES

CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13
Mol. weight
416.573 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Black box warning

Sources

Also known as

  • abbolactone
  • abbolactone
  • abbolactone
  • aldactone
  • aldactone
  • aldactone
  • aldactone
  • aldactone
  • aldazide
  • aldopur
  • berlactone
  • diatensec
  • diatensec
  • espironolactona
  • espironolactona
  • euteberol
  • gx spironol
  • laractone
  • laractone
  • lasilactone
  • quimolactona
  • spiretic
  • spiretic
  • spiroctan 100
  • spiroctan 25
  • spiroctan 50
  • spirolactone
  • spironolacton
  • spironolactone
  • spironolactone
  • spironolactone
  • spironolactone
  • spironolactone
  • spironolactone
  • spironolactone
  • spironolactone
  • spironolactone
  • spironolactone
  • spironolactone
  • spironolactonum
  • spironolactonum
  • spironolattone
  • spironolattone
  • spirospare 100
  • spirospare 25

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07304817Phase 2Feb 28, 2026Boehringer Ingelheim, University of Groningen
NCT07223502Phase 3Dec 1, 2025Sarfez Pharmaceuticals, Inc.
NCT07041281Phase 2Oct 16, 2025Harvard University, University of Pittsburgh
NCT07015671Phase 3Jul 1, 2025Sarfez Pharmaceuticals, Inc.
NCT07043634Phase 3Jun 15, 2025Sarfez Pharmaceuticals, Inc.
NCT07046975Phase 3Jun 15, 2025Sarfez Pharmaceuticals, Inc.
NCT06678685Phase 2/Phase 3 (Phase 3)Oct 30, 2024Shandong University
NCT06523465Phase 4Sep 10, 2024People's Liberation Army of China
NCT06021860Phase 4Jun 30, 2024CMP Therapeutics Ltd
NCT06457074Phase 4Jun 4, 2024Changzhi Medical College, Chongqing Medical University, Southwest Medical University, Zhejiang University, Zhengzhou University
NCT06204640Phase 3Mar 1, 2024University of Caen-Normandie
NCT06499948Phase 4Feb 26, 2024Carol Davila University of Medicine and Pharmacy, Institutul Clinic Fundeni, Bucarest, Romania
NCT05807139Phase 1Jan 3, 2024National Institute on Drug Abuse (NIDA)
NCT06205407Phase 1Dec 26, 2023Pfizer
NCT06164379Phase 4Dec 16, 2023Jiao Tong University
NCT06035978Phase 4Nov 30, 2023University of Ostrava
NCT06004830N/ANov 6, 2023National Institute on Alcohol Abuse and Alcoholism (NIAAA), Yale University
NCT06275763Phase 4Oct 20, 2023Instituto Nacional de Cardiologia de Laranjeiras, Medical University of Warsaw
NCT06005259Phase 4Oct 1, 2023University of Sao Paulo
NCT05995392Early Phase 1 (Phase 1)Aug 31, 2023Yee, Richard W., M.D.
Showing 20 of 226 trials
Page 1 / 12

Organizations

Research & Development (248)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Heart, Lung, and Blood Institute (NHLBI)Government13042002
Harvard UniversityAcademic/Hospital9632008
Vanderbilt UniversityAcademic/Hospital8542005
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Government6122003
National Institutes of Health (NIH)Government6331985
Baylor UniversityAcademic/Hospital5331989
Department of Veteran AffairsGovernment5432003
RelypsaFor profit5332010
University of CopenhagenAcademic/Hospital5532006
Aarhus UniversityAcademic/Hospital4432004
PfizerFor profit4322011
Sarfez Pharmaceuticals, Inc.For profit4412025
Steno Diabetes Center CopenhagenAcademic/Hospital4322003
University of ParisAcademic/Hospital4342010
University of PennsylvaniaAcademic/Hospital4322012
University of VirginiaAcademic/Hospital4422015
AstraZenecaFor profit3322006
British Heart FoundationAcademic/Hospital3032005
Indiana UniversityAcademic/Hospital3322006
Institut National de la Santé Et de la Recherche Médicale, FranceAcademic/Hospital3122012
248 organizations
Page 1 / 13

Marketing (35)

OrganizationOrg typeRelationshipDate
Accord ResearchFor profitMKTGSep 19, 2016
ActavisFor profitMKTGJul 29, 1999
American CyanamidFor profitMKTGAug 4, 1982
Amneal PharmaceuticalsFor profitMKTGJul 2, 2010
Amneal PharmaceuticalsFor profitSYNJul 11, 2022
Amneal PharmaceuticalsFor profitSYNSep 5, 2023
Annora PharmaFor profitMKTGJul 25, 2025
Ascot PharmaceuticalsFor profitMKTGAug 15, 1983
Aurobindo PharmaFor profitMKTGMar 6, 2014
Aurobindo PharmaFor profitSYNMar 6, 2014
CASI Pharmaceuticals, Inc.For profitMKTGJul 10, 1980
CMP Therapeutics LtdFor profitNDA2Aug 4, 2017
Chartwell PharmaceuticalsFor profitMKTGJul 10, 1980
FosunFor profitMKTGJul 10, 1980
G D SearleFor profitNDA2Jan 21, 1960
G D SearleFor profitNDAJan 21, 1960
Graviti PharmaceuticalsFor profitMKTGJan 23, 2025
Hetero Labs LtdFor profitMKTGFeb 21, 2025
IvaxFor profitMKTGMay 7, 1980
Jubilant Innovation Ltd.For profitMKTGApr 23, 2014
LederleFor profitMKTGAug 4, 1982
Mutual PharmaceuticalFor profitMKTGJan 28, 1981
MylanFor profitMKTGAug 3, 1979
Oxford PharmaceuticalsFor profitMKTGAug 29, 2006
PHARMOBEDIENTFor profitMKTGFeb 3, 1981
Parke-DavisFor profitMKTG
PfizerFor profitNDA2Jan 21, 1960
Puracap PharmaceuticalFor profitMKTGNov 6, 1985
Sun PharmaceuticalsFor profitMKTGJul 23, 1986
SuperpharmFor profitMKTGAug 26, 1985
Upsher-Smith LaboratoriesFor profitMKTG
VanguardFor profitMKTGDec 14, 1981
Warner ChilcottFor profitMKTG
Watson PharmaceuticalsFor profitMKTGFeb 23, 1981
Zydus Discovery DMCCFor profitMKTGJul 18, 2018